

OCREVUS (OCRELIZUMAB) ORDER FORM

PATIENT INFORMATION

Patient Name: _____ DOB: _____
 Mobile Number: _____ Patient Weight: _____ kg
 Allergies: _____
 Patient has known difficult venous access. Comments: _____
 New Start Therapy | Continuation of Therapy & Date of last dose (if applicable): _____

DIAGNOSIS (Provider must specify)

- Relapsing-remitting multiple sclerosis (RRMS), ICD 10: G35.A
- Active secondary progressive multiple sclerosis (SPMS), ICD 10: G35.C1
- Active Primary progressive multiple sclerosis (PPMS), ICD 10: G35.B1
- Non-active Primary progressive multiple sclerosis (PPMS), ICD 10: G35.B2
- Clinically isolated syndrome (CIS), ICD 10: G36.9

PROVIDER INFORMATION

Provider Name (print name): _____ Provider NPI: _____
 Signature: _____ Date: _____
 Contact Name: _____ Phone: _____ Fax: _____
 Email Address: _____

Prerequisites to treatment – ensure the following information is complete and attached with referral:

- Demographics Labs and tests supporting diagnosis Office/progress notes

PRE-MEDICATION

Recommendations per PI are selected, these will be given to patient unless otherwise specified.

- Methylprednisolone (Solu-Medrol) 125mg IVP
- Benadryl 25mg PO
- Acetaminophen (Tylenol) 500mg PO
- Famotidine 20mg IV
- Cetirizine (Zyrtec) 10mg PO
- Other: _____ Dose: _____ Route: _____

MEDICATION

MEDICATION	DOSE	ROUTE	FREQUENCY
Ocrevus	<input type="checkbox"/> Initial Treatment: 300 mg at Week 0 and 2, then 600 mg <input type="checkbox"/> Maintenance Treatment: 600 mg	IV	<input type="checkbox"/> Every 24 weeks <input type="checkbox"/> Every 6 months

LABS / SPECIAL INSTRUCTIONS

Order valid for 1 year from date of signature unless otherwise specified here: _____

FAX NUMBERS:

CT: 203.433.0621
 FL: 904.877.9270

MA: 413.296.8482
 MD: 240.224.8607
 ME: 207.407.7272

NC: 919.984.8698
 NH: 603.217.5371
 NJ: 201.581.4521

NY: 631.250.6020
 OH: 937.871.4594
 PA: 610.273.5998

SC: 864.973.6279
 VA: 703.202.0499